Premium
Gamma‐aminobutyric acid levels in cerebrospinal fluid in neuropaediatric disorders
Author(s) -
CortèsSaladelafont Elisenda,
MoleroLuis Marta,
Cuadras Daniel,
Casado Mercedes,
ArmstrongMorón Judith,
Yubero Dèlia,
Montoya Julio,
Artuch Rafael,
GarcíaCazorla Àngels
Publication year - 2018
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/dmcn.13746
Subject(s) - monoamine neurotransmitter , cerebrospinal fluid , gabaergic , neurotransmitter , gamma aminobutyric acid , medicine , endocrinology , neuroscience , chemistry , biology , central nervous system , inhibitory postsynaptic potential , serotonin , receptor
Aim Gamma‐aminobutyric acid ( GABA ) is a major modulator in brain maturation and its role in many different neurodevelopmental disorders has been widely reported. Although the involvement of GABA in different disorders has been related to its regulatory function as an inhibitory neurotransmitter in the mature brain, co‐transmitter, and signalling molecule, little is known about its role as a clinical biomarker in neuropaediatric disorders. The aim of this study is to report the cerebrospinal fluid ( CSF ) free‐ GABA concentrations in a large cohort of patients ( n =85) with different neurological disorders. Method GABA was measured in the CSF of neuropaediatric patients using capillary electrophoresis with laser‐induced fluorescence detection. Other neurotransmitters (amino acids and monoamines) were also analysed. Results GABA concentrations in CSF were abnormal, with a greater frequency (44%) than monoamines (20%) in neuropaediatric patients compared with our reference values. Although we included a few patients with inborn errors of metabolism, GABA levels in CSF were more frequently abnormal in metabolic disorders than in other nosological groups. Interpretation Our work suggests further research into brain GABA ergic status in neuropaediatric disorders, which could also lead to new therapeutic strategies. What this paper adds Homeostasis of GABA seems more vulnerable than that of monoamines in the developing brain. The highest GABA levels are found in the primary GABA neurotransmitter disorder SSADH deficiency. GABA alterations are not specific for any clinical or neuroimaging presentation.